News


All series


All News

In an interview with Targeted Oncology, Partow Kebriaei, MD, discussed the role of transplantation in patients with ALL following treatment with targeted cellular therapies, such as CAR T-cell therapy. She highlights the patient population that receives the most benefit from the use of CAR T-cell therapy and when transplant should be considered for these patients.

Over the last decade, immunotherapeutic options have led to impressive clinical responses in patients with various cancer types and this has increased expectations for successful treatment of the disease. Despite immunotherapy results leading to clinical trials in melanoma, renal cell carcinoma and non–small cell lung cancer, the percentage of patients who respond to immunotherapy remains low; this highlights the need to identify the patient population that will best respond to these approaches.

The FDA has approved acalabrutinib for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma as either an initial or subsequent therapy.

The combination of nivolumab with ipilimumab showed no statistically significant benefit in patients with stage IIIB/C/D or stage IV melanoma compared with nivolumab alone in the phase III CheckMate 915 study, missing the co-primary endpoint of recurrence-free survival  in patients with <1% PD-L1 expression in their tumor cells, according to a press release from Bristol-Myers Squibb.

The phase III B-MIND study of the investigational humanized Fc-engineered monoclonal antibody, tafasitamab plus bendamustine versus rituximab plus bendamustine for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, has passed the pre-planned, event-driven interim analysis for futility, resulting in a recommendation to increase the number of study participants from 330 to 450, according to a press release from MorphoSys.

In an interview with Targeted Oncology, Kathleen Moore, MD, discussed the data surrounding mirvetuximab soravtansine in this patient population and the plans to reevaluate the ADC following the results from the FORWARD I/GOG 3011 clinical trial. She also highlighted other areas of investigation for women with platinum-resistant ovarian cancer.

A supplemental New Drug Application for the combination of ibrutinib and rituximab has been submitted to the FDA for the first-line treatment of patients aged 70 years or younger with chronic lymphocytic leukemia or small lymphocytic lymphoma, according to a press release from ibrutinib developer, AbbVie.

In an interview with Targeted Oncology during the 2019 Prostate Cancer Consensus Conference, James L. Mohler, MD, explained the reasons for changes to the NCCN guidelines on genetic testing and counseling in prostate cancer. He also discussed what needs to be addressed in the future to further increase knowledge of genetic testing and improve its use.